Trial Profile
A Phase 1 Extension Study to Determine the Safety of UC-961 (Cirmtuzumab) at the Recommended Phase 2 Dose for Retreatment of Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Zilovertamab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- 18 Mar 2019 Status changed from active, no longer recruiting to completed.
- 23 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 27 Feb 2017 Status changed from not yet recruiting to recruiting.